Maintenance Therapy

New York, NY—In patients with newly diagnosed multiple myeloma, deep remissions and the prevention of relapse are best achieved by targeted combination therapy very early in the disease, according to Kenneth C.

Despite advances in the treatment of multiple myeloma, survival time is short for many newly diagnosed patients, often because of treatment complications.

Although overall survival (OS) has greatly improved in recent years for patients with multiple myeloma, there are variations and growing disparity for patients of minority race or ethnicity, according to an analysis from the Surveillance, Epidemiology, and End Results (SEER) program. Dianne Pulte, MD, of Thomas Jefferson University in Philadelphia, PA, presented the findings at the 2011 annual meeting of the American Society of Hematology.

San Diego, CA—The value of maintenance therapy in patients with newly diagnosed multiple myeloma who are not eligible for stem-cell transplant (such as the elderly) is still debated. Studies presented at the American Society of Hematology 2011 annual meeting showed that maintenance therapy can delay disease progression, although an overall survival (OS) advantage is not yet evident.

Lenalidomide Maintenance Doubles PFS

Results 1 - 6 of 6
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology